ClinicalTrials.gg
RecruitingNCT07471386Updated Mar 13, 2026

Adjunctive Keratinized Mucosa Augmentation in Peri-Implantitis

An interventional study of Submucosal debridman + saline irrigation and Free gingival graft surgery in Peri-implantitis and Soft Tissue Augmentation at Dental Implants, sponsored by Gazi University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Gazi University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 55 studies in Peri-Implantitis with a site in Turkey — 16 open to participants now, 19 under way, none of them phase 3. Peri-Implantitis · Turkey.

Planned enrollment
20th of 26
30 · median 50
Started
2026
with 9 others
No phase
26 of 55
10 open now
Primary completion
2027-04
later than 13 of 18 live
Registered
40th of 55
by date
Lead sponsor
4 of 55
Gazi University

Among the 55 studies in Peri-Implantitis with a site in Turkey, this one is the 20th largest by planned enrollment of the 26 interventional ones that give a count, is one of 10 that started in 2026, is one of 26 with no phase, reaches primary completion later than 13 of the 18 other live ones, and was the 40th registered.

Peri-Implantitis

324 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.

Browse Peri-Implantitis studies →

Open to participants now

16 of the 55 studies in Peri-Implantitis with a site in Turkey are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 50 Peri-Implantitis studies recruiting now, 28 (56%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Peri-Implantitis with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to increase the width and thickness of peri-implant keratinized mucosa (KM) by transferring a properly dimensioned free gingival graft (FGG) from the palatal donor site and to evaluate its effect as an adjunctive approach to non-surgical peri-implantitis therapy. The procedure is indicated for patients diagnosed with peri-implantitis who present with an inadequate KM (midbuccal KM height \< 2 mm). One month after non-surgical therapy, patients in the test group will undergo keratinized mucosa augmentation using an FGG, while patients in the control group will continue with supportive periodontal therapy and regular follow-up visits. The primary outcome measure of the study is the change in probing depth (PD) at 12 months following peri-implantitis treatment.

Read the detailed description

Background and Case Definition

Peri-implantitis is a disease that typically develops from peri-implant mucositis, an inflammatory condition affecting the soft tissues surrounding dental implants. If left untreated, peri-implant mucositis may progress to peri-implantitis, leading to loss of supporting hard and soft tissues. Clinical signs of peri-implantitis include bleeding on probing (BoP), erythema of the peri-implant mucosa, suppuration, and increased probing depths (PD ≥ 5 mm). The presence of peri-implant bone loss on radiographic examination is a key diagnostic criterion for peri-implantitis.

Although increased width and thickness of keratinized mucosa have been suggested to support peri-implant tissue stability, their role in maintaining peri-implant health and improving the response to peri-implantitis therapy remains controversial. Given the ongoing debate regarding the role of keratinized mucosa dimensions in modulating the response to non-surgical peri-implantitis therapy, further clinical evidence is warranted.

The hypothesis of this study is that adjunctive keratinized mucosa augmentation following non-surgical peri-implantitis therapy results in improved clinical outcomes compared to non-surgical treatment alone. Therefore, the aim of this study was to investigate whether adjunctive keratinized mucosa augmentation improves clinical and radiographic outcomes compared to non-surgical peri-implantitis therapy alone.

Study Population Inclusion Criteria

Systemically healthy adults (≥18 years of age)

Implant-supported restorations in function for at least one year prior to enrollment

Exclusion Criteria

Systemic conditions potentially affecting wound healing or treatment outcomes (e.g., uncontrolled diabetes, active cancer therapy)

Use of medications within the previous three months that could influence healing or inflammation (e.g., anticoagulants, antiplatelet agents, antibiotics, corticosteroids)

Pregnancy or lactation

Smoking ≥10 cigarettes/day

Untreated periodontitis

Malpositioned implants

Previous soft tissue grafting procedures at the implant site

Treatment Protocol

All patients will receive initial non-surgical peri-implantitis therapy, including mechanical debridement of the implant surface using titanium curettes and resin ultrasonic tips, along with saline irrigation for surface decontamination. Oral hygiene instructions will be reinforced in all patients.

In the test group, a free gingival graft procedure will be performed 4-6 weeks after completion of non-surgical therapy to increase the width and thickness of keratinized mucosa.

In the control group, no surgical intervention will be performed following non-surgical therapy, and patients will continue with supportive peri-implant care.

Clinical Parameters

All clinical parameters will be recorded by a calibrated examiner at predefined evaluation time points.

  1. Plaque Index (PI)

    Plaque accumulation will be assessed using the Plaque Index described by O'Leary et al. (1972). The presence or absence of plaque will be recorded at six sites per implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). The plaque index will be expressed as a percentage of sites with visible plaque relative to the total number of assessed sites.

  2. Probing Depth (PD)

    Probing pocket depth will be measured using a William's periodontal probe, positioned parallel to the long axis of the implant. Measurements will be obtained at six sites per implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). The mean value of the six measurements will be calculated and used as the representative PPD value for each implant.

  3. Bleeding on Probing (BoP)

    Bleeding on probing will be assessed according to the criteria proposed by Ainamo and Bay (1975). Following gentle probing of the peri-implant sulcus, bleeding will be recorded as present (+) or absent (-) at six sites per implant. BoP will be expressed as the percentage of bleeding-positive sites.

  4. Width of Keratinized Mucosa (Mid-Buccal)

    The width of keratinized mucosa will be measured in millimeters at the mid-buccal aspect of each implant. Measurements will be taken from the peri-implant soft tissue margin to the mucogingival junction, encompassing both the free and attached keratinized mucosa.

  5. Thickness of Keratinized Mucosa (Mid-Buccal)

    Keratinized mucosa thickness will be assessed using a K-type endodontic file with a silicone stopper. The file will be gently inserted perpendicular to the mucosal surface at the mid-buccal aspect until bone contact is reached. The penetration depth will then be measured using a digital caliper.

  6. Vestibular Depth (Mid-Buccal)

    Vestibular depth will be measured at the mid-buccal aspect of the implant site as the vertical distance from the mucogingival junction to the deepest point of the vestibule. This measurement aims to assess changes in vestibular morphology potentially associated with soft tissue augmentation procedures.

  7. Mucosal Recession (MR)

Peri-implant mucosal recession will be measured as the linear distance (in millimeters) from a fixed reference point on the implant-supported restoration (e.g., the crown margin or implant shoulder) to the most coronal level of the peri-implant soft tissue margin at the mid-buccal aspect. Positive values will indicate apical displacement of the mucosal margin.

03

Conditions studied

  • Peri-implantitis
  • Soft Tissue Augmentation at Dental Implants

Browse trials for

Keywords

  • Peri-implantitis
  • Free gingival graft
  • Inflamation
  • Soft tissue deficiency
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-smoker
  • Systemically healthy
  • Keratinized mucosa witdh \< 2 mm

Exclusion criteria

Exclusion Criteria:

  • İntake of medications that impede periodontal tissue health and healing
  • Pregnancy or lactation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Control group

    Non-surgical treatment of peri-implantitis alone

    Other: Submucosal debridman + saline irrigation

  • Active comparator
    Test Group

    Non-surgical treatment of perı-implantitis + Free gingival graft procedure

    Procedure: Free gingival graft surgery

Interventions

  • OtherSubmucosal debridman + saline irrigation

    Participants diagnosed with peri-implantitis and presenting with insufficient keratinized mucosa (width and thickness \<2 mm) will first receive non-surgical peri-implant therapy. Mechanical debridement of the peri-implant surfaces will be performed using titanium curettes and implant-specific ultrasonic tips in order to remove bacterial biofilm without damaging the implant surface. Additionally, sterile saline solution will be used for submucosal irrigation after mechanical debridement. Patients will receive individualized oral hygiene instructions, including proper brushing techniques, and be suitable for implant-supported restorations. Participants in this group will not receive any surgical or soft tissue grafting procedures.

  • ProcedureFree gingival graft surgery

    Participants diagnosed with peri-implantitis and presenting with insufficient keratinized mucosa (width and thickness \<2 mm) will first receive non-surgical peri-implant therapy. Mechanical debridement of the peri-implant surfaces will be performed using titanium curettes and implant-specific ultrasonic tips in order to remove bacterial biofilm without damaging the implant surface. Additionally, sterile saline solution will be used for submucosal irrigation after mechanical debridement. Patients will receive individualized oral hygiene instructions, including proper brushing techniques, and be suitable for implant-supported restorations. In this group, a free gingival graft (FGG) will be harvested from the palatal donor site under local anesthesia after completion of non-surgical therapy and resolution of acute inflammation.FGG will be stabilized using interrupted or continuous sutures. Participants will be followed for clinical and radiographic evaluations.

06

What researchers measure

Primary outcomes

  1. Change in PPD

    Time frame: Following at 12. months post-treatment

Secondary outcomes

  1. Bleeding on Probing

    Time frame: Following at 12. months post-treatment

  2. Plaque index

    Time frame: Following at 12. months post-treatment

  3. Keratinized mucosa width

    Time frame: Following at 12. months post-treatment

  4. Keratinized mucosa thickness

    Time frame: Following at 12. months post-treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 13 months after the start.

Of 121 non-industry interventional studies with no phase under Peri-Implantitis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 46. This study's planned 13 months is below that.

Counting every sponsor, half of 128 studies reached it within 26 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2026
First posted
Mar 13, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07471386
Lead sponsor
Gazi University
Responsible party
Sıla Çağrı İşler (Professor Dr, Gazi University) — Principal investigator
First posted
Mar 13, 2026
Start date
Mar 1, 2026
Primary completion
Apr 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Mar 13, 2026

Study contacts

Sila Cagri Isler, Prof. Dr.
Contact
silaisler@gazi.edu.tr
+905069966074
Berrin Unsal, Prof Dr
Contact
bunsal@gazi.edu.tr
+905424806416
Sila Cagri Isler, Prof Dr
study director · Gazi University Faculty of Dentistry

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion